Liquid Biopsy in Advanced Prostate Cancer

Area of Science:

• Oncology
• Molecular Diagnostics

Background:

• Prostate cancer presents challenges due to heterogeneity and bone metastases, making tissue biopsy difficult.
• Circulating biomarkers are crucial for managing prostate cancer, offering a less invasive alternative.
• Liquid biopsy enables dynamic characterization of tumor biology, crucial for personalized medicine.

Purpose of the Study:

• To review the role and advancements of liquid biopsy in prostate cancer management.
• To highlight the clinical utility of circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), and extracellular vesicles (EVs).
• To discuss challenges and emerging techniques in liquid biopsy for prostate cancer.

Main Methods:

• Review of current literature on liquid biopsy techniques in prostate cancer.
• Analysis of circulating tumor DNA (ctDNA) for actionable alterations (e.g., BRCA1/2, ATM mutations).
• Evaluation of circulating tumor cells (CTCs) and extracellular vesicles (EVs) for tumor insights.
• Exploration of emerging methods like fragmentomics and methylation profiling.

Main Results:

• ctDNA analysis supports targeted therapy selection and monitoring of treatment response/resistance.
• CTCs and EVs provide complementary information on tumor biology and progression.
• Challenges include sensitivity in low tumor burden and confounding factors like clonal hematopoiesis (CH).
• Newer approaches like fragmentomics and methylation profiling show promise in enhancing tumor specificity.

Conclusions:

• Liquid biopsy, particularly ctDNA, is becoming integral to personalized prostate cancer management.
• Integration of liquid biopsy aids in longitudinal monitoring and treatment adaptation.
• Overcoming current limitations with emerging techniques will further enhance liquid biopsy's clinical utility in prostate cancer.